Rel-1017
Depressive Disorder, Treatment-Resistant
Relmada Therapeutics, Inc.Phase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 89/ 100
Competitive context
91 Active assets in the Depressive Disorder, Treatment-Resistant cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Opc-34712 Dr. Albert Kar-Kin Chung | Phase 4 | A |
S-Ketamine Janssen Korea, Ltd., Korea | Phase 4 | A |
Paroxetine GlaxoSmithKline | Phase 4 | BBB |
S-Ketamine Chinese PLA General Hospital | Phase 4 | BBB |
Saredutant Sanofi | Phase 3 | BBB |
View all 50 →
Same molecule, other indications
Rel-1017 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →